$115.69
0.33% yesterday
Nasdaq, Oct 03, 10:10 pm CET
ISIN
US89377M1099
Symbol
TMDX

TransMedics Group, Inc. Stock price

$115.69
+8.75 8.18% 1M
+44.73 63.04% 6M
+53.34 85.55% YTD
-28.11 19.55% 1Y
+73.46 173.95% 3Y
+101.44 711.86% 5Y
+99.69 623.06% 10Y
+99.69 623.06% 20Y
Nasdaq, Closing price Fri, Oct 03 2025
-0.38 0.33%

Key metrics

Basic
Market capitalization
$3.9b
Enterprise Value
$4.1b
Net debt
$110.3m
Cash
$400.6m
Shares outstanding
34.0m
Valuation (TTM | estimate)
P/E
65.7 | 47.9
P/S
7.4 | 6.4
EV/Sales
7.6 | 6.6
EV/FCF
233.7
P/B
12.4
Financial Health
Equity Ratio
28.4%
Return on Equity
15.5%
ROCE
9.2%
ROIC
15.5%
Debt/Equity
1.6
Financials (TTM | estimate)
Revenue
$531.3m | $613.2m
EBITDA
$76.9m | $139.2m
EBIT
$76.6m | $96.5m
Net Income
$71.7m | $82.2m
Free Cash Flow
$17.4m
Growth (TTM | estimate)
Revenue
48.1% | 38.9%
EBITDA
12,703.3% | 269.3%
EBIT
9,577.4% | 157.3%
Net Income
2,288.7% | 131.9%
Free Cash Flow
109.0%
Margin (TTM | estimate)
Gross
59.8%
EBITDA
14.5% | 22.7%
EBIT
14.4%
Net
13.5% | 13.4%
Free Cash Flow
3.3%
More
EPS
$1.8
FCF per Share
$0.5
Short interest
42.3%
Employees
728
Rev per Employee
$610.0k
Show more

Is TransMedics Group, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,001 stocks worldwide.

TransMedics Group, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a TransMedics Group, Inc. forecast:

13x Buy
72%
5x Hold
28%

Analyst Opinions

18 Analysts have issued a TransMedics Group, Inc. forecast:

Buy
72%
Hold
28%

Financial data from TransMedics Group, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
531 531
48% 48%
100%
- Direct Costs 214 214
52% 52%
40%
318 318
46% 46%
60%
- Selling and Administrative Expenses 177 177
25% 25%
33%
- Research and Development Expense 64 64
14% 14%
12%
77 77
12,703% 12,703%
14%
- Depreciation and Amortization 0.30 0.30
50% 50%
0%
EBIT (Operating Income) EBIT 77 77
9,577% 9,577%
14%
Net Profit 72 72
2,289% 2,289%
13%

In millions USD.

Don't miss a Thing! We will send you all news about TransMedics Group, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

TransMedics Group, Inc. Stock News

Positive
Seeking Alpha
12 days ago
TransMedics remains a strong buy despite recent pullback, driven by seasonal weakness and changing transplant transport trends. TMDX's next-gen OCS heart and lung devices, along with kidney perfusion development, position TMDX for significant growth and market expansion. International markets, especially Europe, Middle East, and Australia, offer substantial growth opportunities and diversificat...
Neutral
PRNewsWire
12 days ago
Modern, purpose-built Mercedez-Benz V-Class fleet to be deployed across four National OCS Program ("NOP") hubs in Italy to support utilization of TransMedics' Organ Care System ("OCS") perfusion technology and increase donor organ utilization for patients in need TransMedics President and Chief Executive Officer, Waleed Hassanein, M.D., to discuss strategic collaboration at upcoming Italian Soc...
Neutral
Seeking Alpha
18 days ago
Concerns about seasonal weakness have dragged TransMedics' share price lower in recent weeks. While TransMedics' growth is moderating, there remains a sizeable growth opportunity within just the U.S. liver market. TMDX's next-gen heart and lung programs, kidney device development, and international expansion could also drive significant growth longer term.
More TransMedics Group, Inc. News

Company Profile

TransMedics Group, Inc. is a commercial stage medical technology company, which engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in October 2018 and is headquartered in Andover, MA.

Head office United States
CEO Waleed Hassanein
Employees 728
Founded 1998
Website www.transmedics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today